Cosentyx, an interleukin-17A inhibitor used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, may interfere with live vaccine administration due to its immune-modulating properties [1].
According to the medication's label and DrugPatentWatch.com [2], Cosentyx can weaken the body's immune response, making patients more susceptible to infections and potentially affecting the efficacy of live vaccines. Live vaccines, such as the MMR (measles, mumps, and rubella) or varicella vaccines, contain a live, attenuated form of the virus that causes the disease [3].
When a patient takes Cosentyx, they may be at a higher risk of developing infections from these vaccines because the medication suppresses the immune system's ability to mount a response against the live virus [4]. As such, patients taking Cosentyx should avoid live vaccines during and after treatment.
It's essential for patients undergoing treatment with Cosentyx to discuss any upcoming vaccinations with their healthcare provider to minimize the risk of vaccine-related complications.
Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK557944/
[2] https://www.drugpatentwatch.com/drug/Cosentyx
[3] https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/live-attenuated-vaccines.html
[4] https://www.fda.gov/media/128950/download